CL2018003510A1 - Anticuerpos antagonistas que se unen en forma de t a tgfb1, tgfb2 y tgfb3 humano, y su uso en el tratamiento de fibrosis pulmonar. - Google Patents

Anticuerpos antagonistas que se unen en forma de t a tgfb1, tgfb2 y tgfb3 humano, y su uso en el tratamiento de fibrosis pulmonar.

Info

Publication number
CL2018003510A1
CL2018003510A1 CL2018003510A CL2018003510A CL2018003510A1 CL 2018003510 A1 CL2018003510 A1 CL 2018003510A1 CL 2018003510 A CL2018003510 A CL 2018003510A CL 2018003510 A CL2018003510 A CL 2018003510A CL 2018003510 A1 CL2018003510 A1 CL 2018003510A1
Authority
CL
Chile
Prior art keywords
tgfb2
tgfb1
bind
treatment
pulmonary fibrosis
Prior art date
Application number
CL2018003510A
Other languages
English (en)
Inventor
Diane Marshall
Daniel John Lightwood
Helene Bon
Joanne Elizabeth Compson
Kate Louise Dixon
Carl Brendan Doyle
Mark Ellis
Sancho Maria Margarida Gouveia
Raymond Anthony Jupp
Lara Kevorkian
Andrew Charles Payne
Joseph Michael David Rastrick
Monika-Sarah Schulze
Alison Turner
Kerry Louise Tyson
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CL2018003510A1 publication Critical patent/CL2018003510A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)

Abstract

LA PRESENTE DIVULGACIÓN SE RELACIONA CON ANTICUERPOS CONTRA EL TGF-BETA Y FRAGMENTOS DE ENLACE DE ESTOS, CON EL ADN QUE CODIFICA LOS MISMOS, CON LAS CÉLULAS HUÉSPEDES QUE COMPRENDEN DICHO ADN ASÍ COMO CON LOS MÉTODOS PARA LA EXPRESIÓN DEL ANTICUERPO O FRAGMENTO DE ENLACE EN UNA CÉLULA HUÉSPED. LA PRESENTE DIVULGACIÓN TAMBIÉN SE EXTIENDE A LAS COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN EL ANTICUERPO O UN FRAGMENTO DE ENLACE DE ESTE ASÍ COMO EL USO DEL ANTICUERPO, FRAGMENTO DE ENLACE Y LAS COMPOSICIONES QUE COMPRENDEN EL MISMO PARA EL TRATAMIENTO DE VARIAS ENFERMEDADES INCLUYENDO LA FIBROSIS.
CL2018003510A 2016-06-08 2018-12-06 Anticuerpos antagonistas que se unen en forma de t a tgfb1, tgfb2 y tgfb3 humano, y su uso en el tratamiento de fibrosis pulmonar. CL2018003510A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1610044.8A GB201610044D0 (en) 2016-06-08 2016-06-08 Antibodies

Publications (1)

Publication Number Publication Date
CL2018003510A1 true CL2018003510A1 (es) 2019-02-01

Family

ID=56508288

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003510A CL2018003510A1 (es) 2016-06-08 2018-12-06 Anticuerpos antagonistas que se unen en forma de t a tgfb1, tgfb2 y tgfb3 humano, y su uso en el tratamiento de fibrosis pulmonar.

Country Status (20)

Country Link
US (2) US10766956B2 (es)
EP (1) EP3468992A1 (es)
JP (1) JP2019520818A (es)
KR (1) KR20190015497A (es)
CN (1) CN109311970A (es)
AR (1) AR108779A1 (es)
AU (1) AU2017276685A1 (es)
BR (1) BR112018074869A2 (es)
CA (1) CA3024011A1 (es)
CL (1) CL2018003510A1 (es)
CO (1) CO2018012513A2 (es)
EA (1) EA201892774A1 (es)
GB (1) GB201610044D0 (es)
IL (1) IL263425A (es)
MX (1) MX2018014376A (es)
RU (1) RU2746926C2 (es)
SG (1) SG11201810311WA (es)
TW (1) TW201802115A (es)
UY (1) UY37279A (es)
WO (1) WO2017211873A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190118172A (ko) 2017-02-08 2019-10-17 드래곤플라이 쎄라퓨틱스, 인크. 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
KR20190120782A (ko) 2017-02-20 2019-10-24 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
CA3090236A1 (en) * 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
MX2020008336A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
AU2020351221A1 (en) * 2019-09-19 2022-05-05 Northwestern University Cost effective culture media and protocol for human induced pluripotent stem cells
KR102270700B1 (ko) * 2019-11-01 2021-06-30 한국과학기술연구원 폐 섬유증의 예방 또는 치료를 위한 올리고뉴클레오티드 중합체와 생체 적합성 양이온성 펩타이드로 이루어지는 폐 특이적 약물 전달체 및 이의 이용
EP4247337A1 (en) * 2020-11-17 2023-09-27 United Therapeutics Corporation Inhaled imatinib for pulmonary hypertension field
CN112961240B (zh) * 2021-04-06 2022-07-05 明济生物制药（北京）有限公司 一种靶向TGF-β1的单克隆抗体及其与间充质干细胞外泌体的联合应用
CN112940119B (zh) * 2021-04-26 2022-05-20 北京芳渟阳生生物科技有限公司 一种单克隆抗体及其与间充质干细胞外泌体的联合应用
WO2023147868A1 (en) * 2022-02-04 2023-08-10 Justus-Liebig-Universität Giessen Inhaled imatinib for treatment of pulmonary hypertension

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020141995A1 (en) * 1997-06-10 2002-10-03 Irvin Charles G. Method for treatment of inflammatory disease
ES2586401T3 (es) 2003-06-16 2016-10-14 Ucb Pharma S.A. Anticuerpos específicos para la esclerostina y métodos para aumentar la mineralización ósea
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
CA2597098C (en) * 2005-02-08 2016-08-02 Steven R. Ledbetter Antibodies to tgfbeta
EP1966243B1 (en) 2005-12-23 2012-02-15 Eli Lilly And Company Tgf-beta binding antibodies
US8642034B2 (en) 2006-10-03 2014-02-04 Genzyme Corporation Use of TGF-β antagonists to treat infants at risk of developing bronchopulmonary dysplasia
KR102577578B1 (ko) * 2011-06-03 2023-09-11 조마 테크놀로지 리미티드 Tgf-베타에 특이적인 항체
UY35384A (es) 2013-03-11 2014-10-31 Genzyme Corp Anticuerpos y fragmentos de unión a antígeno diseñados para unirse al factor de crecimiento transformante ß (TGFß).
CN106794233B (zh) 2014-08-01 2021-11-12 布里格姆及妇女医院股份有限公司 与肺动脉高压的治疗有关的组合物和方法
US11180546B2 (en) 2016-02-17 2021-11-23 Novartis Ag TGFbeta 2 antibodies
EA201991729A1 (ru) 2017-01-20 2019-12-30 Санофи Антитела к tgf-бета и их применение

Also Published As

Publication number Publication date
EP3468992A1 (en) 2019-04-17
BR112018074869A2 (pt) 2019-03-26
SG11201810311WA (en) 2018-12-28
RU2018146158A3 (es) 2020-07-09
UY37279A (es) 2018-01-31
AU2017276685A1 (en) 2018-11-29
CO2018012513A2 (es) 2019-02-08
IL263425A (en) 2018-12-31
US11518803B2 (en) 2022-12-06
JP2019520818A (ja) 2019-07-25
US10766956B2 (en) 2020-09-08
AR108779A1 (es) 2018-09-26
RU2746926C2 (ru) 2021-04-22
CA3024011A1 (en) 2017-12-14
US20190330321A1 (en) 2019-10-31
KR20190015497A (ko) 2019-02-13
TW201802115A (zh) 2018-01-16
MX2018014376A (es) 2019-03-14
EA201892774A1 (ru) 2019-05-31
CN109311970A (zh) 2019-02-05
WO2017211873A1 (en) 2017-12-14
GB201610044D0 (en) 2016-07-20
US20200407436A1 (en) 2020-12-31
RU2018146158A (ru) 2020-07-09

Similar Documents

Publication Publication Date Title
CL2018003510A1 (es) Anticuerpos antagonistas que se unen en forma de t a tgfb1, tgfb2 y tgfb3 humano, y su uso en el tratamiento de fibrosis pulmonar.
UY37635A (es) Anticuerpos anti phf-tau y sus usos
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
CY1121934T1 (el) Αντισωματα anti-fcrn
CO2019006485A2 (es) Anticuerpos y metodos de su utilizacion
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
BR112017022845A2 (pt) neoepítopos de câncer
UY35718A (es) Anticuerpos anti-csf-1r: métodos de expresión de los mismos.
CL2016003191A1 (es) Polipéptidos receptores formulados y métodos relacionados
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
CU20170023A7 (es) Anticuerpos y receptores de antígeno quiméricos específicos para cd19
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
BR112017014230A2 (pt) endófitos de semente através de cultivares e espécies, composições associadas e métodos de uso dos mesmos
AR092188A1 (es) ANTICUERPOS HUMANOS PARA GFRa3 Y METODOS PARA SU USO
AR101400A1 (es) Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
ECSP19087742A (es) Anticuerpos anti-garp-tgf-b
UY35483A (es) Anticuerpos pac1 humanos
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
CO2017000558A2 (es) Variantes de proteínas de unión al factor h
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer